이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Inhibikase Therapeutics 관리

관리 기준 확인 1/4

Inhibikase Therapeutics' CEO는 Milton Werner, Jun2010 에 임명되었습니다 의 임기는 13.25 년입니다. 총 연간 보상은 $ 744.06K, 67.3% 로 구성됩니다. 67.3% 급여 및 32.7% 보너스(회사 주식 및 옵션 포함). 는 € 1.16M 가치에 해당하는 회사 주식의 16.63% 직접 소유합니다. 1.16M. 경영진과 이사회의 평균 재임 기간은 각각 8.9 년과 2.8 년입니다.

주요 정보

Milton Werner

최고 경영자

US$744.1k

총 보상

CEO 급여 비율	67.3%
CEO 임기	13.3yrs
CEO 소유권	16.6%
경영진 평균 재임 기간	8.9yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Milton Werner 의 보수는 Inhibikase Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$744k	US$501k	-US$18m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$611k	US$455k	-US$15m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$7m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$961k	US$293k	-US$3m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$3m
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$385k	US$293k	-US$6m
Sep 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$4m
Dec 31 2018	US$535k	US$452k	-US$2m

보상 대 시장: Milton 의 총 보상 ($USD 744.06K )은 German 시장( $USD 434.78K ).

보상과 수익: 회사가 수익성이 없는 동안 Milton 의 보상이 증가했습니다.

CEO

Milton Werner (59 yo)

13.3yrs

테뉴어

US$744,055

보상

Dr. Milton H. Werner, Ph D., serves as the Chief Executive Officer and President at Inhibikase Therapeutics, Inc. since June 2010. Prior to founding Inhibikase, From May 2007 until August 2008, Dr. Werner...

리더십 팀

이름	위치	테뉴어	보상	소유권
Milton Werner	CEO, President & Director	13.3yrs	US$744.06k	16.63% $ 1.2m
Joseph Frattaroli	Chief Financial Officer	5.4yrs	US$574.77k	0.012% $ 859.0
Roger Rush	Head of Preclinical Research	8.7yrs	데이터 없음	데이터 없음
Surendra Singh	Head of Chemistry	9.1yrs	데이터 없음	데이터 없음
Charles Olanow	CEO of Clintrex Research Corporation & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Dan Williams	Controller	no data	데이터 없음	데이터 없음

8.9yrs

평균 재임 기간

경험이 풍부한 관리: IQT0 의 관리팀은 노련하고 경험 (평균 재직 기간 8.9 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Milton Werner	CEO, President & Director	13.3yrs	US$744.06k	16.63% $ 1.2m
Charles Olanow	CEO of Clintrex Research Corporation & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Paul Grint	Independent Director	2.8yrs	US$84.62k	0% $ 0
Dennis Berman	Independent Director	2.8yrs	US$78.62k	0% $ 0
Kenneth Marek	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jeffrey Kordower	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Roy Freeman	Independent Director	2.8yrs	US$69.62k	0% $ 0
Robert Hauser	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Karl Kieburtz	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gisele Dion	Independent Director	less than a year	US$58.89k	데이터 없음
Ted Dawson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Valina Dawson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: IQT0 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Inhibikase Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Inhibikase Therapeutics Receives a Letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

Inhibikase Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Full year 2021 earnings released: US$0.81 loss per share (vs US$0.35 loss in FY 2020)

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.082 loss in 3Q 2020)

Inhibikase Therapeutics, Inc. Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.052 loss in 2Q 2020)

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell Microcap Value Index

Inhibikase Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

Full year 2020 earnings released: US$0.35 loss per share (vs US$0.70 loss in FY 2019)

Inhibikase Therapeutics, Inc. Announces Update on Phase 1 Clinical Trial of IkT-148009

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from NASDAQ Composite Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령